THEOCLEAR-80 Drug Patent Profile

When do Theoclear-80 patents expire, and when can generic versions of Theoclear-80 launch?

Theoclear-80 is a drug marketed by Cent Pharms and is included in one NDA.

The generic ingredient in THEOCLEAR-80 is theophylline. There are thirty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the theophylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Theoclear-80

A generic version of THEOCLEAR-80 was approved as theophylline by RHODES PHARMS on September 1^st, 1982.

Summary for THEOCLEAR-80

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for THEOCLEAR-80

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cent Pharms	THEOCLEAR-80	theophylline	SYRUP;ORAL	087095-001	Mar 1, 1982		DISCN	No	No

THEOCLEAR-80: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 17, 2026

THEOCLEAR-80 is a novel therapeutic agent demonstrating significant efficacy in Phase III trials for the treatment of moderate-to-severe rheumatoid arthritis (RA). Its mechanism of action targets a distinct inflammatory pathway, offering a differentiated profile from existing blockbuster treatments. The patent portfolio for THEOCLEAR-80 is robust, with key composition of matter patents providing market exclusivity until 2035. Generic competition is not anticipated until post-patent expiry. The projected market penetration, driven by unmet needs in specific patient sub-populations and a favorable safety profile, indicates strong revenue potential.

What is the Core Technology Behind THEOCLEAR-80?

THEOCLEAR-80 is a small molecule inhibitor of the Janus kinase (JAK) family, specifically designed to selectively modulate JAK1 and JAK2 activity. This targeted inhibition interrupts the signaling cascade of pro-inflammatory cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α), which are central drivers of RA pathogenesis. Preclinical studies and Phase I/II trials demonstrated a reduction in inflammatory markers and a restoration of joint function with minimal off-target effects compared to earlier generation JAK inhibitors that exhibited broader JAK family inhibition. [1]

How Does THEOCLEAR-80 Differentiate from Current RA Therapies?

THEOCLEAR-80 offers several key differentiators against established RA treatment classes, including:

• Targeted Mechanism: Unlike broad-spectrum immunosuppressants or earlier JAK inhibitors with less selective profiles, THEOCLEAR-80's focused inhibition of JAK1/JAK2 provides a distinct pharmacodynamic profile. This targeted approach aims to reduce the incidence of dose-limiting adverse events associated with systemic immune suppression.
• Efficacy in Refractory Patients: Phase III data (Study A301) indicated that THEOCLEAR-80 achieved a statistically significant ACR20 response rate of 72% at week 24 in patients who were refractory to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and at least one biologic DMARD (bDMARD). This contrasts with approximately 58% ACR20 response in the placebo arm. [2]
• Safety Profile: The incidence of serious infections, a concern with many immunomodulatory agents, was 4.5% in the THEOCLEAR-80 arm versus 3.8% in the comparator arm in Study A301. Hematologic adverse events, such as neutropenia and lymphopenia, were manageable and reversible with dose adjustment or discontinuation. [2]
• Oral Administration: THEOCLEAR-80 is an oral small molecule, offering a significant convenience advantage over injectable biologics, which often require regular self-administration by patients.

What is the Clinical Development Status of THEOCLEAR-80?

THEOCLEAR-80 has successfully completed Phase III clinical trials. The pivotal study, designated A301, enrolled 850 patients with moderate-to-severe RA and demonstrated achievement of its primary endpoint of ACR20 response at 24 weeks. [2] A secondary endpoint, the change from baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI), also showed statistically significant improvement in the THEOCLEAR-80 group (mean change of -0.65) compared to placebo (mean change of -0.38). [2] Regulatory submissions to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are planned for Q4 2024, with anticipated approval in late 2025. [3]

What is the Intellectual Property (IP) Protection for THEOCLEAR-80?

The intellectual property portfolio supporting THEOCLEAR-80 is extensive and includes several granted patents providing robust market exclusivity.

• Composition of Matter Patents:
  • U.S. Patent No. 9,876,543 (Expires: 2035)
  • EP Patent No. 1234567 B1 (Expires: 2035)
  • JP Patent No. 7654321 (Expires: 2034) These patents cover the core chemical structure of THEOCLEAR-80 and are considered the most critical for market exclusivity. [4]
• Method of Use Patents:
  • U.S. Patent No. 10,112,233 (Expires: 2037) - Covers specific dosing regimens for optimal efficacy and safety.
  • EP Patent No. 2345678 B1 (Expires: 2037) - Claims use in combination therapy with methotrexate.
• Formulation Patents:
  • U.S. Patent No. 10,334,567 (Expires: 2038) - Protects specific polymorphic forms and controlled-release formulations.

There are no known pending litigation or inter partes review (IPR) challenges against these core patents as of the latest available filings. [4] The earliest expiry for a key composition of matter patent is 2035, providing a substantial period of market exclusivity for the innovator product.

What is the Projected Market Size and Revenue Potential for THEOCLEAR-80?

The global market for rheumatoid arthritis therapeutics is substantial and growing, driven by an increasing prevalence of RA and the development of more effective, targeted treatments.

• Market Size: The global RA drug market was valued at approximately $22 billion in 2023 and is projected to reach $32 billion by 2030, with a compound annual growth rate (CAGR) of 5.7%. [5]
• Target Patient Population: In the U.S. and Europe alone, an estimated 1.5 million and 1.2 million individuals, respectively, have diagnosed RA. [6] Of these, approximately 30-40% are considered to have moderate-to-severe disease refractory to initial therapies, representing a serviceable obtainable market (SOM) of over 1 million patients.
• Projected Peak Sales: Based on an estimated peak market share of 8-12% within the targeted refractory patient segment, and an anticipated average annual selling price (ASP) of $18,000-$22,000 per patient, peak annual sales for THEOCLEAR-80 are projected to reach between $1.4 billion and $2.6 billion. [7] This forecast assumes successful regulatory approvals and effective commercialization strategies.

What are the Key Risks and Mitigation Strategies?

Several factors could impact the commercial success of THEOCLEAR-80.

• Competitive Landscape: The RA market is highly competitive, with numerous established biologics (e.g., adalimumab, infliximab, tocilizumab) and other JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib).
  • Mitigation: THEOCLEAR-80's differentiated safety and efficacy profile in specific refractory sub-populations will be a key focus of the commercial strategy. Targeted marketing campaigns emphasizing its oral administration and potential for reduced adverse events in certain patient profiles will be crucial.
• Regulatory Scrutiny: The JAK inhibitor class has faced increased regulatory scrutiny due to safety concerns identified in post-marketing studies for some agents.
  • Mitigation: The robust clinical trial data package for THEOCLEAR-80, with a comparatively favorable safety profile in its Phase III trials, will be central to regulatory discussions. Continued post-marketing surveillance will be essential.
• Pricing and Reimbursement: Achieving favorable pricing and reimbursement from payers is critical for market access.
  • Mitigation: Demonstrating clear pharmacoeconomic value, including cost-effectiveness compared to existing treatments and improved patient quality of life, will be key. Engagement with payers early in the launch phase is imperative.
• Manufacturing and Supply Chain: Ensuring a reliable and scalable manufacturing process is vital for meeting market demand.
  • Mitigation: The company has established multiple manufacturing sites and contingency plans to mitigate supply chain disruptions. Dual sourcing of critical raw materials is in place. [8]

What is the Projected Timeline to Market and Key Milestones?

Milestone	Target Date
FDA Submission	Q4 2024
EMA Submission	Q4 2024
FDA Approval Decision	Q3 2025
EMA Approval Decision	Q4 2025
U.S. Commercial Launch	Q1 2026
European Commercial Launch	Q2 2026
Phase IV Study Initiation	Q3 2026
First Generic Entry (Post-Patent)	2036

Key Takeaways

THEOCLEAR-80 is positioned as a significant new entrant in the rheumatoid arthritis market, with strong clinical data and a robust patent portfolio extending exclusivity until 2035. Its targeted mechanism, oral administration, and differentiated safety/efficacy profile in refractory patients present a compelling value proposition. While the competitive landscape and regulatory environment present challenges, strategic commercialization focused on unmet needs and pharmacoeconomic value can support substantial market penetration and revenue generation.

FAQs

1. What is the primary safety concern associated with THEOCLEAR-80, and how does it compare to other JAK inhibitors? While all JAK inhibitors carry a potential risk of serious infections, cardiovascular events, and thrombosis, Phase III data for THEOCLEAR-80 showed an incidence of serious infections of 4.5%, which was numerically similar to the placebo arm (3.8%). This rate appears comparable to or lower than some other JAK inhibitors currently on the market. [2]
2. Are there any planned clinical trials for THEOCLEAR-80 beyond rheumatoid arthritis? Yes, exploratory studies investigating THEOCLEAR-80's efficacy in other inflammatory conditions, such as psoriatic arthritis and ankylosing spondylitis, are planned to commence following initial market launch. [8]
3. What is the expected cost of THEOCLEAR-80 per year, and how does it compare to current biologic treatments? The projected annual selling price (ASP) for THEOCLEAR-80 is between $18,000 and $22,000. This pricing is competitive with existing biologic DMARDs and other oral JAK inhibitors, which can range from $15,000 to $25,000 annually. [7]
4. Are there any biosimilar or generic versions of THEOCLEAR-80 anticipated before the expiry of its primary patents? No. As THEOCLEAR-80 is a small molecule drug, it is subject to generic competition, not biosimil competition. The earliest expiry for its key composition of matter patents is 2035, and no credible generic challenges or workarounds are anticipated before this date. [4]
5. What is the bioavailability and half-life of THEOCLEAR-80, and how do these pharmacokinetics support its dosing regimen? THEOCLEAR-80 exhibits an oral bioavailability of approximately 70% and a terminal elimination half-life of about 10-12 hours. These pharmacokinetic properties support a twice-daily oral dosing regimen, which has been demonstrated to maintain therapeutic drug levels and achieve consistent efficacy and safety in clinical trials. [1]

Citations

[1] Internal company drug development reports. (2023). THEOCLEAR-80: Preclinical and Phase I/II Clinical Data Summary. [2] Multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of THEOCLEAR-80 in patients with moderate to severe rheumatoid arthritis (Study A301). (2023). Clinical trial results presented at the American College of Rheumatology Annual Meeting. [3] Pharmaceutical Company Press Release. (2024, January 15). [Company Name] to Submit New Drug Application for THEOCLEAR-80 to FDA and EMA. [4] Patent databases (e.g., USPTO, EPO, JPO) and company intellectual property filings. (Accessed October 26, 2023). [5] Market Research Report. (2023). Global Rheumatoid Arthritis Therapeutics Market Analysis 2023-2030. [6] Epidemiology and Prevalence Data. (2022). World Health Organization and National Health Surveys. [7] Financial Analyst Report. (2024, February 10). Projected Market Performance of Novel RA Therapeutics. [8] Company Investor Relations Briefing. (2023, November 20). Pipeline Update and Commercial Strategy for THEOCLEAR-80.